CSRXP: BIG PHARMA BACK AT IT WITH EGREGIOUS PRICE HIKES OUTPACING INFLATION TO RING IN 2025
Jan 2, 2025
Brand Name Drug Companies Signal Business-as-Usual Approach to Price-Gouging… Read More
© 2025 CSRXP- All Rights Reserved
Press & Statements
CSRxP: DISAPPOINTED CONGRESS DID NOT PASS CORNYN-BLUMENTHAL AND Q1/Q2 REFORMS TO HOLD BIG PHARMA ACCOUNTABLE, INCREASE COMPETITION
Dec 21, 2024
Campaign Will Work with Lawmakers in the New Congress and the New… Read More
CSRxP: PASSAGE OF CORNYN-BLUMENTHAL AND Q1/Q2 REFORMS WOULD BE POSITIVE STEPS TOWARD HOLDING BIG PHARMA ACCOUNTABLE FOR PATENT ABUSE
Dec 17, 2024
Bipartisan, Market-Based Solutions Would Crack Down on Big Pharma’s Patent… Read More
ICYMI: CSRxP ANALYSIS FINDS PHARMACEUTICAL INDUSTRY’S PROFIT MARGINS TEN TIMES GREATER THAN OTHER SECTORS OF DRUG SUPPLY CHAIN
Dec 17, 2024
Study Finds Big Pharma’s Price-Gouging and Patent Abuse Playbook Fuels… Read More
CSRxP: USPTO WITHDRAWAL OF PATENT THICKET RULE ADDS TO URGENCY FOR CONGRESS TO PASS CORNYN-BLUMENTHAL
Dec 4, 2024
Lawmakers Must Act to Hold Big Pharma Accountable for Egregious Patent Abuse… Read More
CSRxP STATEMENT ON SENATE JUDICIARY MARKUP OF THE PREVAIL ACT
Nov 21, 2024
Congress Should Not Further Consider Misguided Proposal That Would Enable More… Read More
CSRxP ANALYSIS FINDS PHARMACEUTICAL INDUSTRY’S PROFIT MARGINS TEN TIMES GREATER THAN OTHER SECTORS OF DRUG SUPPLY CHAIN
Nov 20, 2024
Study Finds Big Pharma’s Price-Gouging and Patent Abuse Playbook Fuels… Read More
CSRxP: SENATE JUDICIARY COMMITTEE SHOULD REJECT PHARMA-SUPPORTED POLICIES THAT WOULD UNDERMINE BIPARTISAN PROGRESS ON PATENT ABUSE
Nov 12, 2024
Lawmakers Should Remain Focused on Holding Big Pharma Accountable for… Read More
CSRxP: SENATE JUDICIARY COMMITTEE SHOULD REJECT PHARMA-SUPPORTED POLICIES THAT WOULD UNDERMINE BIPARTISAN PROGRESS ON PATENT ABUSE
Sep 25, 2024
Lawmakers Should Remain Focused on Holding Big Pharma Accountable for… Read More
CSRxP ENCOURAGES HELP COMMITTEE TO ADVANCE BIPARTISAN SOLUTIONS TO PROMOTE GREATER COMPETITION IN THE PRESCRIPTION DRUG MARKET
Sep 24, 2024
Legislation Scheduled for Thursday Markup Would Encourage Adoption of… Read More
CSRxP: BIG PHARMA’S EGREGIOUS GLP-1 PRICES AND ANTI-COMPETITIVE TACTICS UNSUSTAINABLE FOR PATIENTS AND U.S. HEALTH CARE SYSTEM
Sep 24, 2024
HELP Committee Hearing an Opportunity to Highlight Staggering Cost… Read More
CSRxP JOINS FELLOW ADVOCATES FOR LOWER DRUG PRICES TO URGE HOUSE JUDICIARY COMMITTEE TO CRACK DOWN ON BIG PHARMA’S PATENT ABUSE
Sep 6, 2024
Letter Encourages Lawmakers to Advance Bipartisan Solutions to Hold Big Pharma… Read More